SCHEMBL309573

SCHEMBL309573

CCS(=O)(=O)c1cc(O)cc(Br)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
PSIP1 O75475 2/20 0.39
GAA P10253 1/20 0.35
PLCG1 P19174 1/20 0.33
DDR1 Q08345 2/20 0.33
POLB P06746 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
CYP3A4 P08684 1/20 0.31
PTGS1 P23219 1/20 0.31
DRD3 P35462 1/20 0.31
ESR1 P03372 1/20 0.31
LMNA P02545 2/20 0.31
APEX1 P27695 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310175 0.87 ALDH1A1 (0.33) ALDH1A1KMT2AMEN1GAAPOLB
SCHEMBL18503820 0.85 PSIP1 (0.46) ALDH1A1KMT2AMEN1PSIP1GAA
SCHEMBL30633579 0.79 ENPP2 (0.46) TDP1CYP3A4LMNA
SCHEMBL309415 0.79 ENPP2 (0.46) TDP1CYP3A4LMNA
SCHEMBL17262653 0.77 LMNA (0.44) ALDH1A1KMT2AMEN1GAAPLCG1
SCHEMBL28692251 0.75 CA2 (0.50) CYP2C19APEX1
SCHEMBL309556 0.73 LMNA (0.40) ALDH1A1KMT2AMEN1PSIP1POLB
SCHEMBL19274297 0.73 LOX (0.47) ALDH1A1KMT2AMEN1PSIP1GAA
SCHEMBL12325101 0.71 HTT (0.44) ALDH1A1KMT2AMEN1GAAPOLB
SCHEMBL2642996 0.69 PSIP1 (0.56) ALDH1A1PSIP1GAACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093253-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 US disclosed
US-8093253-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 US disclosed
US-8093253-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 US disclosed
CN-101970401-A Leukotriene b4 inhibitors HOFFMANN LA ROCHE 2011-02-09 CN disclosed
EP-2250150-A1 LEUKOTRIENE B4 INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-11-17 EP disclosed
WO-2009109483-A1 LEUKOTRIENE B4 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
WO-2009109483-A1 LEUKOTRIENE B4 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-09-10 US disclosed
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-09-10 US disclosed
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S ALDH1A1 685/4885KMT2A 4432/4885MEN1 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.